Haemonetics (NYSE:HAE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Haemonetics (NYSE:HAE) from a hold rating to a buy rating in a report released on Saturday.

Several other research analysts have also commented on the company. Robert W. Baird lifted their price target on Haemonetics from $87.00 to $99.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Raymond James Financial restated an “outperform” rating and set a $90.00 price objective on shares of Haemonetics in a research report on Friday, November 14th. Citigroup reduced their target price on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, October 7th. Barrington Research increased their price target on shares of Haemonetics from $86.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Haemonetics in a report on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $84.40.

Haemonetics Trading Up 1.1%

HAE opened at $82.90 on Friday. The firm has a market capitalization of $3.88 billion, a price-to-earnings ratio of 24.24, a price-to-earnings-growth ratio of 1.55 and a beta of 0.29. The company’s 50 day simple moving average is $78.31 and its two-hundred day simple moving average is $65.92. Haemonetics has a 1-year low of $47.31 and a 1-year high of $87.32. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, beating the consensus estimate of $1.12 by $0.15. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The firm had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. During the same quarter last year, the firm earned $1.12 earnings per share. The business’s revenue for the quarter was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Analysts expect that Haemonetics will post 4.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

Several large investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Haemonetics by 3.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock valued at $1,877,000 after purchasing an additional 971 shares during the period. Caxton Associates LLP acquired a new stake in shares of Haemonetics in the first quarter valued at $216,000. United Services Automobile Association purchased a new stake in shares of Haemonetics in the 1st quarter valued at $212,000. Empowered Funds LLC lifted its stake in Haemonetics by 9.1% during the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock worth $283,000 after acquiring an additional 372 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Haemonetics by 6.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after acquiring an additional 9,051 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Closed acquisition of Vivasure expands Haemonetics’ device pipeline into percutaneous vessel closure, strengthening product mix and M&A-driven growth optionality. Haemonetics Acquires Vivasure Medical
• Positive Sentiment: Deal details: Haemonetics will pay up to €185M (including earnouts) for Vivasure — a meaningful but manageable acquisition price that investors view as strategic investment in high‑growth procedure tools. Haemonetics to shell out up to €185M to acquire device maker Vivasure
• Positive Sentiment: Third‑party seller Orchestra BioMed to receive up to $21M from the transaction — confirms deal close and cash flow moving to sellers, underscoring the transaction’s completion. Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
• Positive Sentiment: Barrington Research raised its price target to $93 and kept an outperform stance, signaling analyst confidence in upside after recent strategic moves. HAE price target raised by Barrington
• Positive Sentiment: BTIG reiterated a Buy rating — further analyst support that may sustain positive sentiment and buying interest. BTIG Reiterates Buy Rating for Haemonetics
• Positive Sentiment: Zacks highlights Haemonetics as a strong growth stock based on style scores, supporting momentum and growth narratives for investors focused on fundamentals. Here’s Why Haemonetics (HAE) is a Strong Growth Stock
• Neutral Sentiment: Analyst‑coverage roundup summarizes mixed broker views and consensus — useful context but no single new catalyst. Where Haemonetics Stands With Analysts
• Neutral Sentiment: Market commentary examines valuation after recent share gains — suggests upside is now increasingly a function of execution on guidance and M&A integration. How Recent Moves Are Rewriting The Haemonetics (HAE) Story On Guidance And Valuation
• Negative Sentiment: Some analysts/commentators argue the share re‑rating is complete and suggest taking profits now, which could pressure the stock if momentum stalls. Haemonetics: Re-Rating Complete, Time To Cash In

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.